Your browser doesn't support javascript.
loading
Preparation and characterization of cyclodextrin nanosponges for bortezomib delivery.
Allahyari, Saeideh; Valizadeh, Hadi; Roshangar, Leila; Mahmoudian, Mohammad; Trotta, Francesco; Caldera, Fabrizio; Jelvehgari, Mitra; Zakeri-Milani, Parvin.
Afiliación
  • Allahyari S; Faculty of Pharmacy, Tabriz University of Medical Science , Tabriz, Iran.
  • Valizadeh H; Student Research Committee, Tabriz University of Medical Science , Tabriz, Iran.
  • Roshangar L; Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Science , Tabriz, Iran.
  • Mahmoudian M; Stem Cell Research Center and Department of Anatomical Sciences, Faculty of Medicine, Tabriz University of Medical Science , Tabriz, Iran.
  • Trotta F; Faculty of Pharmacy, Tabriz University of Medical Science , Tabriz, Iran.
  • Caldera F; Chemistry Department, University of Torino , Turin, Italy.
  • Jelvehgari M; Chemistry Department, University of Torino , Turin, Italy.
  • Zakeri-Milani P; Faculty of Pharmacy, Tabriz University of Medical Science , Tabriz, Iran.
Expert Opin Drug Deliv ; 17(12): 1807-1816, 2020 12.
Article en En | MEDLINE | ID: mdl-32729739
BACKGROUND: Bortezomib (BTZ) as an anticancer drug has been used through the injection pathway. RESEARCH DESIGN AND METHODS: Two types of Cyclodextrin nanosponges (CDNSs) were synthesized and studied by DLS, TEM, FTIR, and DSC instruments for BTZ delivery. Both carriers were analyzed for loading efficiencies and in-vitro release. Cell studies and intestinal permeability of selected CDNS were determined using MTT and SPIP method, respectively. RESULTS: Both types of CDNSs, encapsulated BTZ in their nano-porous structure, but better loading was shown in CDNS 1:4. FTIR and DSC results proved considerable encapsulation of BTZ into CDNSs. The slow and prolonged release profile was observed for CDNS 1:4 in comparison with CDNS 1:2. Based on in-vitro results, BTZ-CDNS 1:4 was chosen as a selected nanosystem for further analysis. This nontoxic carrier revealed considerable uptake (93.9% in 3 h) against the MCF-7 cell line but indicated higher IC50 in comparison with the plain drug. This carrier also could improve the rat intestinal permeability of BTZ almost 5.8 times. CONCLUSION: CDNS 1:4 has the ability to be introduced as a nontoxic carrier for BTZ delivery with its high loading, controlled release manner, high cellular uptake, and permeability improvement characteristics.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ciclodextrinas / Bortezomib / Antineoplásicos Límite: Animals / Humans / Male Idioma: En Revista: Expert Opin Drug Deliv Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2020 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ciclodextrinas / Bortezomib / Antineoplásicos Límite: Animals / Humans / Male Idioma: En Revista: Expert Opin Drug Deliv Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2020 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido